Total Intravenous Anesthesia (TIVA): What the Evidence Says

Total intravenous anesthesia, or TIVA, maintains general anesthesia through an intravenous line rather than with inhaled agents — usually a propofol infusion with an analgesic such as remifentanil, delivered by manually controlled or target-controlled infusion pumps. What matters to a practice is when its measurable advantages justify its specific delivery requirements.

The measurable advantage

The best-studied advantage of TIVA is a lower rate of postoperative nausea and vomiting (PONV). In a randomized factorial trial of 5,199 patients at high risk for PONV published in the New England Journal of Medicine, replacing volatile anesthetics with propofol lowered the relative risk of PONV by about 19%, while each antiemetic studied reduced it by about 26%; propofol combined with avoidance of nitrous oxide produced a reduction similar to that of an individual antiemetic.¹ The Fourth Consensus Guidelines for the Management of PONV recommend propofol-based anesthesia as one strategy to reduce baseline risk in susceptible patients.²

Recovery characteristics vary between patients and techniques, and TIVA should not be presented as guaranteeing a clearer or faster awakening. Because it avoids volatile agents altogether, TIVA is one option for patients with a known or suspected susceptibility to malignant hyperthermia, whose anesthetic plan must also avoid succinylcholine; regional anesthesia may be appropriate in some cases.

Delivery safeguards and monitoring

TIVA can be delivered safely by appropriately trained anesthesia professionals using reliable infusion systems, appropriate monitoring, and safeguards against interrupted drug delivery and accidental awareness. The joint guidelines from the Association of Anaesthetists and the Society for Intravenous Anaesthesia recommend TIVA-specific infusion safeguards, appropriate pump programming, inspection of the intravenous access whenever practical, and processed EEG monitoring when neuromuscular blocking drugs are used with TIVA.³

Awareness with recall is rare — the ASA's practice advisory on intraoperative awareness and brain function monitoring reports an incidence of 0.1–0.2% — but it can leave lasting psychological sequelae, and that advisory discusses brain-function monitoring as an option for patients judged to be at increased risk.⁴ For a practice this is a monitoring specification, not a clinical abstraction: it belongs in the coverage agreement rather than in the judgment call made on the day of the case.

Case selection

Propofol-based TIVA may be useful when reducing PONV risk is a priority, including for patients with previous PONV or motion sickness. Procedure type and other clinical considerations also inform the choice. Practices should coordinate technique selection with Dr. Seitz after individualized review of patient risk and procedural requirements.

TIVA in an office setting

Where no anesthesia machine or scavenging system is installed, TIVA removes the need for volatile delivery. It also transfers the principal risk to the delivery system itself: an interrupted infusion, a disconnected line or an occluded cannula can leave a patient lighter than intended, and a patient under neuromuscular blockade cannot signal it. The joint Association of Anaesthetists and Society for Intravenous Anaesthesia guidelines therefore specify TIVA-specific infusion safeguards, appropriate pump programming, inspection of intravenous access whenever practical, and processed EEG monitoring when neuromuscular blocking drugs are used.³ A practice running TIVA should be able to show that those safeguards are in place.

Pairing TIVA with a procedure-specific block

The ASA's January 2026 practice guideline on perioperative pain management using local and regional analgesia strongly recommends fascial plane blocks to reduce pain and opioid requirements in the first 24 hours after open cardiothoracic, abdominal, retroperitoneal and pelvic surgery and after mastectomy in adults, and conditionally recommends them for minimally invasive cardiothoracic procedures and open hernia repair.⁵ The task force reports that its analysis was limited by low methodologic quality, inconsistent outcome measurement and small sample sizes.⁵ The practical consequence is a two-part pathway rather than a single technique: a propofol-based anesthetic that lowers PONV risk, combined with the regional or local component the practice's own case mix supports. Neither substitutes for the other, and the guideline's own cautions argue against treating fascial plane blocks as a default.

Sources

1. Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350(24):2441–2451.
2. Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2020;131(2):411–448.
3. Nimmo AF, Absalom AR, Bagshaw O, et al. Guidelines for the safe practice of total intravenous anaesthesia (TIVA): joint guidelines from the Association of Anaesthetists and the Society for Intravenous Anaesthesia. Anaesthesia. 2019;74(2):211–224.
4. American Society of Anesthesiologists Task Force on Intraoperative Awareness. Practice advisory for intraoperative awareness and brain function monitoring: a report by the American Society of Anesthesiologists Task Force on Intraoperative Awareness. Anesthesiology. 2006;104(4):847–864.
5. Joshi GP, Mariano ER, Elkassabany NM, et al. 2026 American Society of Anesthesiologists practice guideline on perioperative pain management using local and regional analgesia for cardiothoracic surgeries, mastectomy, and abdominal surgeries. Anesthesiology. 2026;144(1):19–43.